Balyasny Asset Management L.P. Makes New $3.09 Million Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Balyasny Asset Management L.P. acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 33,536 shares of the medical instruments supplier's stock, valued at approximately $3,090,000. Balyasny Asset Management L.P. owned about 0.15% of LeMaitre Vascular as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its position in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares during the last quarter. KBC Group NV grew its position in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares during the last quarter. Huntington National Bank lifted its holdings in LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after buying an additional 455 shares during the period. Finally, Empowered Funds LLC acquired a new position in LeMaitre Vascular during the 4th quarter worth about $150,000. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Trading Up 1.8%

LeMaitre Vascular stock traded up $1.47 during midday trading on Friday, reaching $84.77. The stock had a trading volume of 140,295 shares, compared to its average volume of 164,599. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a market capitalization of $1.92 billion, a P/E ratio of 46.32, a PEG ratio of 2.22 and a beta of 0.86. The company has a fifty day moving average price of $84.19 and a two-hundred day moving average price of $92.94.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same period in the previous year, the firm earned $0.44 earnings per share. The business's quarterly revenue was up 12.0% on a year-over-year basis. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular's payout ratio is 40.40%.

Analysts Set New Price Targets

LMAT has been the topic of several recent research reports. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. Finally, Lake Street Capital boosted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $98.14.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.